Twist Bioscience Is Maintained at Market Perform by Leerink Partners
Twist Bioscience Analyst Ratings
Leerink Partners Maintains Twist Bioscience(TWST.US) With Hold Rating, Raises Target Price to $48
Positive Outlook and Strong Pricing Strategy Justify Buy Rating for Twist Bioscience
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $55
Barclays Sticks to Their Buy Rating for Twist Bioscience (TWST)
Baird Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $46
Twist Bioscience Is Maintained at Outperform by Evercore ISI Group
Twist Bioscience Analyst Ratings
Evercore Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $56
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Scotiabank Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $50
Scotiabank Remains a Buy on Twist Bioscience (TWST)
Twist Bioscience Price Target Raised to $35.00/Share From $28.00 by JP Morgan
Baird Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $46
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $46
Twist Bioscience Analyst Ratings
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $55
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), RegenXBio (RGNX)